Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queen's University at Kingston, Ontari...( SAN FRANCISCO July 7 /- This is a fu...),Health

SAN FRANCISCO, July 7 /PRNewswire-FirstCall/ -- "This is a fully equipped bio-safety level 2 laboratory dedicated exclusively to Medizone research," stated Dr. Michael Shannon Director of Medical Affairs for Medizone. "This new laboratory is located in the heart of one of the finest bio-medical communities in the country and will provide a primary research and development platform for the Corporation as it proceeds down what is now a clear path to commercialization with its lead product, AsepticSure(TM). Given the outstanding range of bactericidal kill rates we have achieved to date ( 4.4 log /99.994% to 5 log /99.999%) with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand our scientific horizons through collaborative arrangements in many diverse and exciting new applications. The current pandemic of H1 N1 influenza occurring world-wide reminds us how vulnerable we are to new infectious diseases and why new advanced and innovative technologies that combat such infectious agents are seriously needed. The Medizone AsepticSure(TM) system is just such an innovation in the battle against infections which claim countless lives every day world-wide. The Company now has a platform to continue an expanded laboratory research program even as it prepares for the commencement of hospital beta testing of its hospital sterilization system later this summer."

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4 quarter of this year.

This press release
'/>"/>